RYET Licenses Cogni AI to BioNexus Gene Lab for Malaysia
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
RYET Enters Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
KUALA LUMPUR, Malaysia, Oct. 05, 2026 -- Ruanyun Edai Technology Inc. (NASDAQ: RYET) announced that it has signed a definitive agreement to grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) an exclusive license for its Cogni AI document-intelligence platform in Malaysian healthcare, alongside a reciprocal share exchange. The agreement marks the expansion of Cogni AI into a new industry and market outside China, aligning with Malaysia's ongoing efforts to accelerate public healthcare digitalization.
Under the terms of the agreement, RYET will be entitled to a 10 percent royalty on qualifying technology receipts collected by BGLC and its affiliates. In addition, BGLC will issue 560,000 shares at closing, including 150,000 shares in exchange for 500,000 new RYET ordinary shares, establishing a direct reciprocal stake between the partners.
Key Agreement Details
- License Terms: An initial ten-year term, renewable at BGLC's option for two additional five-year terms, totaling up to 20 years of exclusive rights in Malaysian healthcare.
- Consideration and Shares: BGLC will issue 410,000 common shares for the license, valued contractually at USD 3.5 million, plus the additional share exchange.
- Royalties and Expansion: A 10 percent royalty applies to qualifying receipts, with options for BGLC to expand the technology into other local industries such as education.
